Local
CARsgen's CAR-T Product Satri-cel Included in China's Commercial Health Insurance Innovative Drug List
Meet in Common connects news with real conversations. Use ThinkMatch to arrange a Roundtable and meet people to discuss this story.
Source: Moulton Advertiser
SHANGHAI, Nov. 14, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that satricabtagene autoleucel ("satri-cel", product code: CT041), an autologous CAR T-cell therapy product targeting Claudin18.2, has been…
This excerpt comes from the named source. Read the original for the full reporting.
Read the original at Moulton Advertiser
